Angiographic Findings in Patients with Hepatocellular Carcinoma Previously Treated Using Proton Beam Therapy

Table 3

Relationship between PBT-related angiographic findings and the elapsed time after PBT treatment.

	All patients		Single PBT treatment; (n=25)		Multiple PBT treatments; (n=6)
	Follow-up after first PBT, days	Follow-up after last PBT, days	N	Follow-up after PBT, days	N	Follow-up after first PBT, days	Follow-up after last PBT, days
Abnormal staining of irradiated liver parenchyma (n=22)	629; (109–3,163)	466.5; (109–3,163)	17	477; (109–3,163)	5	225; (464–720)	877; (1,274–1,950)
Development of tortuous tumor feeder (n=13)	911; (381–2,938)	559; (381–2,938)	9	699; (381–2,938)	4	466.5; (441–720)	1,284.5; (911–1,950)
Development of extrahepatic collateral pathway (n=7)	917; (418–31,63)	917; (418–3,163)	7	917; (418–3,163)	0	N/A	N/A
Development of AP/AV shunt (n=4)	588; (397–1,443)	588; (397–1,443)	4	588; (397–1,443)	0	N/A	N/A

Data are reported as median (range).
TACE: transarterial chemoembolization, TAI: transcatheter arterial infusion, PBT: proton beam therapy, HCC: hepatocellular carcinoma, AP/AV: arterio-portal or arteriovenous.